Bristol Myers Squibb acquires Orum’s ORM-6151 programme for up to $180m
ORM-6151 is an anti-CD33 antibody-enabled GSPT1 degrader intended to treat acute myeloid leukaemia (AML) and other CD33-expressing malignancies,…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
07 Nov 23
ORM-6151 is an anti-CD33 antibody-enabled GSPT1 degrader intended to treat acute myeloid leukaemia (AML) and other CD33-expressing malignancies,…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
07 Nov 23
The Transaction remains subject to the sanction of the Scheme by the High Court of Justice of England…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
03 Nov 23
Through the drug product business, Cambrex has been delivering services around product development, clinical and commercial manufacturing, and…
01 Nov 23
GSK intends to evaluate JNJ-3989 in a sequential regimen with bepirovirsen, its investigational antisense oligonucleotide designed to identify…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
30 Oct 23
SecureDose is a private pharmaceutical research and development firm, dedicated to creating synthetic versions of already available drugs…
24 Oct 23
The Swiss drugmaker will make an upfront of $7.1bn and a near-term milestone payment of $150m, for rights…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
20 Oct 23
The European Commission has unconditionally approved the transaction, concluding that the proposed transaction would not significantly reduce competition…
18 Oct 23
The partnership will initially focus on Assembly Bio’s next-gen core inhibitor ABI-4334, intended for HBV, long-acting helicase-primase inhibitor…
16 Oct 23
NewChem Technologies is a contract services provider and supplies customers in pharmaceuticals, diagnostics and biotechnology to veterinary science…
12 Oct 23
The microbiome mapping technology provider has acquired the assets to scale the discovery, development, and production of microbiome-based…